Table 3.

Multivariable analysis of prognostic factors for nasopharyngeal carcinoma patients (combination of AKR1C4 and EBV DNA included)

Endpoint	Factor	HR (95% CI)	P a
LRFS
	AKR1C4 + EBV DNA
	Intermediate risk vs. low	5.182 (1.451–18.505)	0.011
	High risk vs. low	7.596 (1.736–33.248)	0.007
	T stage (4 vs. 1/2/3)	6.102 (0.740–50.285)	0.093
	N stage (2/3 vs. 0/1)	1.245 (0.498–3.114)	0.640
	Disease stage (IVa vs. I/II/III)	0.377 (0.046–3.097)	0.364
	BMI (≥ 18.5 vs. < 18.5 kg/m2)	0.465 (0.099–2.181)	0.331
	Smoking history (yes vs. no)	1.752 (0.746–4.114)	0.198
OS
	AKR1C4 + EBV DNA
	Intermediate risk vs. low	2.345 (0.985–5.581)	0.054
	High risk vs. low	3.567 (1.380–9.224)	0.009
	T stage (4 vs. 1/2/3)	3.425 (1.121–10.471)	0.031
	N stage (2/3 vs. 0/1)	3.863 (1.717–8.693)	0.001
	Disease stage (IVa vs. I/II/III)	0.781 (0.248–2.461)	0.673
	BMI (≥ 18.5 vs. < 18.5 kg/m2)	0.378 (0.146–0.979)	0.045
	Smoking history (yes vs. no)	1.577 (0.806–3.806)	0.183
PFS
	AKR1C4 + EBV DNA
	Intermediate risk vs. low	2.310 (1.172–4.552)	0.016
	High risk vs. low	3.601 (1.688–7.684)	0.001
	T stage (4 vs. 1/2/3)	2.588 (1.091–4.603)	0.031
	N stage (2/3 vs. 0/1)	2.520 (1.379–4.603)	0.003
	Disease stage (IVa vs. I/II/III)	0.976 (0.407–2.340)	0.956
	BMI (≥ 18.5 vs. < 18.5 kg/m2)	0.518 (0.223–1.201)	0.125
	Smoking history (yes vs. no)	1.679 (0.996–2.830)	0.052
DMFS
	AKR1C4 + EBV DNA
	Intermediate risk vs. low	1.835 (0.820–4.106)	0.140
	High risk vs. low	2.993 (1.248–7.176)	0.014
	T stage (4 vs. 1/2/3)	1.851 (0.752–4.559)	0.181
	N stage (2/3 vs. 0/1)	4.009 (1.798–8.937)	0.001
	Disease stage (IVa vs. I/II/III)	1.456 (0.569–3.727)	0.433
	BMI (≥ 18.5 vs. < 18.5 kg/m2)	0.383 (0.159–0.919)	0.032
	Smoking history (yes vs. no)	1.655 (0.886–3.091)	0.114

Abbreviations: BMI Body mass index CI Confidence interval, DMFS Distant metastasis-free survival, EBV DNA Epstein-Barr virus deoxyribonucleic acid, HR Hazard ratio, LRFS Locoregional relapse-free survival, OS Overall survival, PFS Progression-free survival

^aBoldface letter: significant